Literature DB >> 28521201

Validation of the use of an artificial mitochondrial reporter DNA vector containing a Cytomegalovirus promoter for mitochondrial transgene expression.

Yuma Yamada1, Takuya Ishikawa1, Hideyoshi Harashima2.   

Abstract

Mitochondria have their own gene expression system that is independent of the nuclear system, and control cellular functions in cooperation with the nucleus. While a number of useful technologies for achieving nuclear transgene expression have been reported, only a few have focused on mitochondria. In this study, we validated the utility of an artificial mitochondrial DNA vector with a virus promoter on mitochondrial transgene expression. We designed and constructed pCMV-mtLuc (CGG) that contains a CMV promotor derived from Cytomegalovirus and an artificial mitochondrial genome with a NanoLuc (Nluc) luciferase gene that records adjustments to the mitochondrial codon system. Nluc luciferase activity measurements showed that the pCMV-mtLuc (CGG) efficiently produced the Nluc luciferase protein in human HeLa cells. Moreover, we optimized the mitochondrial transfection of pCMV-mtLuc (CGG) using a MITO-Porter system, a liposome-based carrier for mitochondrial delivery via membrane fusion. As a result, we found that transfection of pCMV-mtLuc (CGG) by MITO-Porter modified with the KALA peptide (cationic amphipathic cell-penetrating peptide) showed a high mitochondrial transgene expression. The developed mitochondrial transgene expression system represents a potentially useful tool for the fields of nanoscience and nanotechnology for controlling the intracellular microenvironment via the regulation of mitochondrial function and promises to open additional innovative research fields of study.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CMV promotor; Hydrodynamic injection; Mitochondria; Mitochondrial delivery; Transgene expression

Mesh:

Substances:

Year:  2017        PMID: 28521201     DOI: 10.1016/j.biomaterials.2017.05.016

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  6 in total

1.  Leber's Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development.

Authors:  Cuneyt Karaarslan
Journal:  Adv Ther       Date:  2019-10-11       Impact factor: 3.845

Review 2.  Engineering Genetic Systems for Treating Mitochondrial Diseases.

Authors:  Yoon-Ha Jang; Sae Ryun Ahn; Ji-Yeon Shim; Kwang-Il Lim
Journal:  Pharmaceutics       Date:  2021-05-28       Impact factor: 6.321

Review 3.  Recent Advances in Mitochondria-Targeted Gene Delivery.

Authors:  Yoon-Ha Jang; Kwang-Il Lim
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

4.  Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene.

Authors:  Yuma Yamada; Kana Somiya; Akihiko Miyauchi; Hitoshi Osaka; Hideyoshi Harashima
Journal:  Sci Rep       Date:  2020-05-05       Impact factor: 4.379

Review 5.  Therapeutic Strategies for Regulating Mitochondrial Oxidative Stress.

Authors:  Yuma Yamada; Yuta Takano; Jiro Abe; Mitsue Hibino; Hideyoshi Harashima
Journal:  Biomolecules       Date:  2020-01-05

Review 6.  Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine.

Authors:  Yuma Yamada; Yusuke Sato; Takashi Nakamura; Hideyoshi Harashima
Journal:  J Control Release       Date:  2020-09-08       Impact factor: 9.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.